Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer

Advanced hormone-sensitive prostate cancer responds to androgen-deprivation therapy (ADT); however, therapeutic options for recurrent castration-resistant disease are limited. Because growth hormone-releasing hormone (GHRH) and GHRH receptor (GHRH-R) are regulated in an autocrine fashion in prostate...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Fahrenholtz, Cale D., Rick, Ferenc G., Garcia, Maria I., Zarandi, Marta, Cai, Ren-Zhi, Block, Norman L., Schally, Andrew V., Burnstein, Kerry L.
Format: Artigo
Jezik:Inglês
Izdano: National Academy of Sciences 2014
Teme:
Biological Sciences
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3903215/
https://ncbi.nlm.nih.gov/pubmed/24395797
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1323102111
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items